<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; practices</title>
	<atom:link href="http://www.tapanray.in/tag/practices/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pills and Payments: India&#8217;s Unethical Drug Marketing Problem</title>
		<link>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pills-and-payments-indias-unethical-drug-marketing-problem</link>
		<comments>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/#comments</comments>
		<pubDate>Fri, 27 Jun 2025 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[unethical]]></category>
		<category><![CDATA[Vikshit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10925</guid>
		<description><![CDATA[The recent exposé by The Economic Times, titled &#8220;Rx Name Unethical practitioners,&#8221; published on June 19, 2025, which brought to light allegations of a prominent global pharmaceutical company sponsoring extravagant foreign trips for doctors in violation of ethical codes, serves as &#8230; <a href="http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pills-and-payments-indias-unethical-drug-marketing-problem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UCPMP 2024: Game Changer or False Dawn?</title>
		<link>http://www.tapanray.in/ucpmp-2024-game-changer-or-false-dawn/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ucpmp-2024-game-changer-or-false-dawn</link>
		<comments>http://www.tapanray.in/ucpmp-2024-game-changer-or-false-dawn/#comments</comments>
		<pubDate>Tue, 19 Mar 2024 08:10:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[dawn]]></category>
		<category><![CDATA[false]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP 2024]]></category>
		<category><![CDATA[Uniform]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10859</guid>
		<description><![CDATA[On March 12, 2024, the Department of Pharmaceuticals (DoP) of the Government of India notified the new Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024. Having gone through the details, many construe that aiming to finally clean up pharmaceutical marketing practices &#8230; <a href="http://www.tapanray.in/ucpmp-2024-game-changer-or-false-dawn/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ucpmp-2024-game-changer-or-false-dawn/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leverage Increased Focus On ‘Self-Care’ For Better Patient Outcomes</title>
		<link>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leverage-increased-focus-on-self-care-for-better-patient-outcomes</link>
		<comments>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/#comments</comments>
		<pubDate>Mon, 24 Jan 2022 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infectious]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[messaging]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[non-infectious]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[ovid-19]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[self-care]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10640</guid>
		<description><![CDATA[‘People have been practicing self-care for thousands of years. Now an increase in self-care interventions is shifting the way health care is perceived, understood, and accessed, and adding to the many medicines, diagnostics, and technologies available for people to use &#8230; <a href="http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Enhancing Pharma Brand Experience In The New Normal</title>
		<link>http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=enhancing-pharma-brand-experience-in-the-new-normal</link>
		<comments>http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 22 Jun 2020 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[approaches]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[journey]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[mapping]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[restart]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[touchpoint]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unlock down]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10137</guid>
		<description><![CDATA[In these days of unprecedented and all-pervasive disruptions &#8211; almost in every facet of life &#8211; caused by an unknown virus, scramble to find an effective solution for saving lives and livelihoods, still continue. The discomfiture seems to be omnipresent &#8230; <a href="http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/enhancing-pharma-brand-experience-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Opioid Crisis: A Looming Threat To India?</title>
		<link>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=opioid-crisis-a-looming-threat-to-india</link>
		<comments>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/#comments</comments>
		<pubDate>Mon, 16 Sep 2019 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Atypical]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[flip side]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[looming]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[narcotics]]></category>
		<category><![CDATA[Nexus]]></category>
		<category><![CDATA[Opioid]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[tryst]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9712</guid>
		<description><![CDATA[A serious, but a typical health crisis that has shaken America, is now, apparently, in search of its prey in India – a soft target to ignite a raging fire of misuse or abuse of prescription drugs of addictive in &#8230; <a href="http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Are Cancer Patients Victims of Pharma’s Payment to Doctors &#8211; For Prescriptions?</title>
		<link>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions</link>
		<comments>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/#comments</comments>
		<pubDate>Mon, 04 Mar 2019 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Evaluation]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pay]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Prescribing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[relatioship]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9432</guid>
		<description><![CDATA[In pharma industry, people of all socioeconomic backgrounds have no other choice but to visit doctors, to seek their expert advice for medical treatment. Patients expect them to prescribe the right and most affordable medicines for desired relief. Ironically, it &#8230; <a href="http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Uniting Pharma With Business Ethics: A Bridge Too Far?</title>
		<link>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=uniting-pharma-with-business-ethics-a-bridge-too-far</link>
		<comments>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/#comments</comments>
		<pubDate>Mon, 18 Feb 2019 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[bridge]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[gift]]></category>
		<category><![CDATA[IFPMA]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[promotional]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reminders]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[uniting]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9414</guid>
		<description><![CDATA[Operating ethically not only is the right thing to do but also is fundamental to success in business. Poor governance and poor ethical business practices can lead to fines, public scrutiny and distrust – overshadowing good performance, destroying reputation, and &#8230; <a href="http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/uniting-pharma-with-business-ethics-a-bridge-too-far/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With ‘Cutting Corners’ Going North, Pharma Reputation Dives South</title>
		<link>http://www.tapanray.in/with-cutting-corners-going-north-pharma-reputation-dives-south/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-cutting-corners-going-north-pharma-reputation-dives-south</link>
		<comments>http://www.tapanray.in/with-cutting-corners-going-north-pharma-reputation-dives-south/#comments</comments>
		<pubDate>Mon, 15 Jan 2018 00:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[campaign]]></category>
		<category><![CDATA[Corners]]></category>
		<category><![CDATA[cut]]></category>
		<category><![CDATA[cutting]]></category>
		<category><![CDATA[diving]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[George W. Merck]]></category>
		<category><![CDATA[group]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Lobby]]></category>
		<category><![CDATA[north]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rejuvenation]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[serving]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8735</guid>
		<description><![CDATA[Just a few months ago, on October 24, 2017, ‘New Jersey Law Journal’ came out with an eye-catching headline &#8211; “Sanofi Set to Pay $ 61M Settlement in Antitrust Suit Over Vaccine Bundling.” The suit says: &#8220;Sanofi-Pasteur allegedly suppressed competition &#8230; <a href="http://www.tapanray.in/with-cutting-corners-going-north-pharma-reputation-dives-south/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-cutting-corners-going-north-pharma-reputation-dives-south/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Governance Maladies and Corporate Leadership</title>
		<link>http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-governance-maladies-and-corporate-leadership</link>
		<comments>http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/#comments</comments>
		<pubDate>Sun, 01 Oct 2017 23:37:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Bioavailability]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[Board]]></category>
		<category><![CDATA[centered]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Dinesh]]></category>
		<category><![CDATA[Directors]]></category>
		<category><![CDATA[doctrine]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Independent]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[maladies]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[managers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[senior]]></category>
		<category><![CDATA[shareholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thakur]]></category>
		<category><![CDATA[Theory]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[Whistleblower]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8444</guid>
		<description><![CDATA[On September 26, 2017, two media headlines related to the Indian pharma industry, possibly made many wonder &#8211; Are these some of the key reasons prompting the Government to enforce stringent and costly regulations in this sector? Above revelations came &#8230; <a href="http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Marketing Practices: Why Pharma Does What It Does?</title>
		<link>http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=marketing-practices-why-pharma-does-what-it-does</link>
		<comments>http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/#comments</comments>
		<pubDate>Mon, 11 Sep 2017 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Allergan]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[Brent]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CME]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Jimenez]]></category>
		<category><![CDATA[Joe]]></category>
		<category><![CDATA[Joseph]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[pharma. policy]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[proposals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Saunders]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8408</guid>
		<description><![CDATA[It started way back &#8211; spanning across many developed countries of the world. However, probably for the first time in the last five years, an international media group focused on this issue thriving in India, with so much detail. Reuters &#8230; <a href="http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/marketing-practices-why-pharma-does-what-it-does/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
